Data Supplement from Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop
Year: 2023
Type: other
Abstract: Supplementary Figure 1. A drug screen reveals dipyridamole as potentiating the anti-proliferative effects of atorvastatin and fluvastatin. Supplementary Figure 2. Dipyridamole enhances the effects of statin-induced MVA pathway inhibition. Supplementary Figure 3. The relative sensitivity to doxorubicin in 8226DOX and 8226 parental cells is not significantly altered in response to dipyridamole exposure. Supplementary Figure 4. Dipyridamole prevents the statin induced upregulation of HMGCR and HMGCS1. Supplementary Figure 5. Dipyridamole prevents the statin induced upregulation of HMGCR and HMGCS1 through inhibition of SREBP2 cleavage in OCI-AML2 cells. Supplementary Figure 6: Working model of how dipyridamole potentiates the anticancer effects of statins. Supplementary Table 1. Composition of the chemical library.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362421297